Organoids technology for advancing the clinical translation of cancer nanomedicine
WIREs Nanomedicine and Nanobiotechnology · 2023-09 · 15 (5)
DOI: 10.1002/wnan.1892 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, online erschienen am 23.04.2023. Verfasst von Dong-Kun Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, China. Hauptthemen laut MEDLINE: Nanomedicine, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 120 Literaturangaben. Gefördert von: Guangdong Provincial Pearl River Talents Program, Basic and Applied Basic Research Foundation of Guangdong Province, National Key Research and Development Program of China.
Abstract (Originalsprache)
The past decades have witnessed the rapid development and widespread application of nanomedicines in cancer treatment; however, the clinical translation of experimental findings has been low, as evidenced by the low percentage of commercialized nanomedicines. Incomplete understanding of nanomedicine‐tumor interactions and inappropriate evaluation models are two important challenges limiting the clinical translation of cancer nanomedicines. Currently, nanomedicine‐tumor interaction and therapeutic effects are mainly investigated using cell lines or mouse models, which do not recapitulate the complex tumor microenvironment in human patients. Thus, information obtained from cell lines and mouse models cannot provide adequate guidance for the rational redesign of nanomedicine. Compared with other preclinical models, tumor organoids constructed from patient‐derived tumor tissues are superior in retaining the key histopathological, genetic, and phenotypic features of the parent tumor. We speculate that organoid technology would help elucidate nanomedicine‐tumor interaction in the tumor microenvironment and guide the design of nanomedicine, making it a reliable tool to accurately predict drug responses in patients with cancer. This review highlighted the advantages of drug delivery systems in cancer treatment, challenges limiting the clinical translation of antitumor nanomedicines, and potential application of patient‐derived organoids (PDO) in nanomedicine. We propose that combining organoids and nanotechnology would facilitate the development of safe and effective cancer nanomedicines and accelerate their clinical application. This review discussed the potential translational value of integrative research using organoids and cancer nanomedicine. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, China.
- Shenzhen Bay Laboratory, Shenzhen, China.
- National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou, China.
- Key Laboratory of Biomedical Engineering of Guangdong Province, and Innovation Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou, China.
- Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education, South China University of Technology, Guangzhou, China.
ORCID-Profile: Jun Wang
Förderung
- Guangdong Provincial Pearl River Talents Program
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Zhao, D. K., Liang, J., Huang, X. Y., Shen, S., & Wang, J. (2023). Organoids technology for advancing the clinical translation of cancer nanomedicine. WIREs Nanomedicine and Nanobiotechnology, 15(5). https://doi.org/10.1002/wnan.1892
Vancouver
Zhao DK, Liang J, Huang XY, Shen S, Wang J. Organoids technology for advancing the clinical translation of cancer nanomedicine. WIREs Nanomedicine and Nanobiotechnology. 2023;15(5). doi:10.1002/wnan.1892
BibTeX
@article{Zhao2023,
author = {Zhao, Dong-Kun and Liang, Jie and Huang, Xiao-Yi and Shen, Song and Wang, Jun},
title = {Organoids technology for advancing the clinical translation of cancer nanomedicine},
journal = {WIREs Nanomedicine and Nanobiotechnology},
year = {2023},
volume = {15},
number = {5},
doi = {10.1002/wnan.1892}
}
EUVIMED